Download PDFPDF

Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Infliximab therapy for refractory adult-onset Still's disease
    • Petros P Sfikakis
    • Other Contributors:
      • Alexios Kokkinos, Alexios Iliopoulos, George D Kitas

    Dear Editor,

    We read with interest the observational, retrospective study by Fautrel and colleagues on the efficacy of anti-TNFƒÑ agents (aTNF) in refractory adult onset Still¡¦s disease (AOSD) [1].

    The authors conclude that aTNF is not as effective in AOSD as in rheumatoid arthritis (RA) or the spondyloarthrotopathies and may be helpful only in some AOSD cases. This conclusion cannot be fully supporte...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Still's disease and anti-TNF alpha therapy: the pediatric experience

    Dear Editor,

    Fautrel et al [1] recently reported the cases of 20 adults with Still's disease who were treated with TNF alpha blocking agents. Most patients only achieved partial remission and there were only 2 cases of sustained remission of more than one year, which contrasts with the much higher response rates observed in patients with rheumatoid arthritis.

    In this paper, the authors never refer...

    Show More
    Conflict of Interest:
    None declared.